Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study.
Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study.
复制标题
DOI：
10.1155/2021/2670502
复制
发表时间：
2021
影响因子：
1.8
通讯作者：
Grotz TE
中科院分区：
文献类型：
--
作者：
MacArthur TA;Harmsen WS;Mandrekar J;Abraha F;Grotz TE
早发性胃癌（EOGC，诊断时年龄≤ 60岁）现在占美国新发胃癌的30%以上。假设质子泵抑制剂（PPI）的慢性酸抑制可能促进肿瘤发生，而其他药物（包括他汀类药物、非甾体抗炎药（NSAID）、二甲双胍和环氧合酶-2（考克斯-2）抑制剂）已被提议为保护性药物。我们的目的是评估使用上述常用处方药与EOGC发展之间的关联。 我们使用了一个基于人口的医疗记录链接系统，以确定1995年1月1日至2020年12月31日期间明尼苏达州奥姆斯特德县的EOGC病例。根据诊断时的年龄、性别、吸烟状况和体重指数（BMI），将患者与对照组1：1匹配。采用条件Logistic回归分析与EOGC发生几率的相关性。 在研究期间确定了96例EOGC病例。在单变量和多变量回归分析中，PPI、他汀类药物、NSAID或二甲双胍的使用与EOGC发生之间无显著相关性。在最终的多变量模型中，在癌症诊断前使用考克斯-2抑制剂6个月或更长时间，EOGC的几率显著降低（OR = 0.39，95%CI 0.16 - 0.94）。 在这项对明尼苏达州奥姆斯特德县人群进行的回顾性研究中，我们发现在诊断前使用考克斯-2抑制剂6个月或更长时间可显著降低EOGC的发生几率，但EOGC的发生与PPI和其他常用处方药的使用无关。
Early-onset gastric cancer (EOGC, age ≤ 60 years at diagnosis) now comprises >30% of new gastric cancers in the United States. It is hypothesized that chronic acid suppression with proton-pump inhibitors (PPIs) may promote tumorigenesis, while other medications including statins, nonsteroidal anti-inflammatory drugs (NSAIDs), metformin, and cyclooxygenase-2 (COX-2) inhibitors have been proposed as protective. We aimed to assess for an association between use of the aforementioned commonly prescribed medications and EOGC development. We used a population-based medical record linkage system, to identify cases of EOGC in Olmsted County, Minnesota, between January 1, 1995, and December 31, 2020. Patients were matched 1 : 1 with controls based on age at diagnosis, sex, smoking status, and body mass index (BMI). Conditional logistic regression was used to examine associations with the odds of EOGC development. Ninety-six cases of EOGC were identified during the study period. On both univariate and multivariate regression analysis, there was no significant association between use of PPIs, statins, NSAIDs, or metformin and EOGC development. In a final multivariable model, there was a significant reduction in odds of EOGC with COX-2 inhibitor use for six months or more prior to cancer diagnosis (OR = 0.39, 95% CI 0.16-0.94). In this retrospective, population-based study of individuals in Olmsted County, MN, we found significantly reduced odds of EOGC development associated with COX-2 inhibitor use for six months or more prior to diagnosis, but no association between EOGC development and use of PPIs and other commonly prescribed medications.
登录
查看更多内容
影响因子：
3.8
作者：
Cheung, Ka Shing;Chan, Esther W.;Leung, Wai K.
通讯作者：
Leung, Wai K.
影响因子：
29.4
作者：
Moayyedi, Paul;Eikelboom, John W.;Yusuf, Salim
通讯作者：
Yusuf, Salim
影响因子：
3.8
作者：
Moore, Assaf;Hikri, Elad;Aharon, Irit Ben
通讯作者：
Aharon, Irit Ben
影响因子：
7.6
作者：
Sanduleanu, S;Jonkers, D;Stockbr端gger, RW
通讯作者：
Stockbr端gger, RW
影响因子：
5.2
作者：
Kwon TJ;Kim TJ;Lee H;Min YW;Min BH;Lee JH;Kim JJ
通讯作者：
Kim JJ